Retatrutide FDA Approval Timeline: Complete 2026-2028 Roadmap to Launch
Last updated February 5, 2026
As of early 2026, Retatrutide (LY3437943) remains the most anticipated "next-generation" weight loss medication in the global pharmaceutical pipeline. Following the historic Phase 3 data released in December 2025—which confirmed an average weight loss of 28.7%—Eli Lilly is now entering the final stages of clinical testing and regulatory preparation.
The Master Timeline: When Will Retatrutide Be Available?
While early results are groundbreaking, Retatrutide is not yet FDA-approved and cannot be legally prescribed outside of authorized clinical trials. Based on current Phase 3 completion dates and standard FDA review cycles, here is the projected roadmap to pharmacy availability:
2026: The Year of Data Readouts
- January – May 2026: Final "Primary Completion" dates for core TRIUMPH Phase 3 trials, including TRIUMPH-1 (Obesity) and TRIUMPH-2 (Type 2 Diabetes).
- Late 2026: Eli Lilly is expected to submit its New Drug Application (NDA) to the FDA once the full Phase 3 data package is analyzed.
2027: The FDA Review Window
- Early 2027: Potential for the FDA to grant Priority Review, which could shorten the standard 10-month review cycle to just 6 months.
- Mid-2027: The earliest plausible window for an official FDA approval decision, assuming no major safety hurdles or requests for additional data.
2028: Market Launch & Widespread Access
- Early 2028: Projected commercial launch in the United States.
- 2028 & Beyond: Production ramp-up and expansion into international markets.
Key Phase 3 Trial Milestones (TRIUMPH Program)
The TRIUMPH clinical trial program is evaluating Retatrutide across more than 5,800 participants to ensure safety and efficacy for various health conditions.
| Trial Name | Focus Area | Status / Est. Completion |
|---|---|---|
| TRIUMPH-1 | Obesity or Overweight (General) | Estimated May 2026 |
| TRIUMPH-2 | Obesity + Type 2 Diabetes | Estimated 2026 |
| TRIUMPH-3 | Obesity + Cardiovascular Disease | Estimated May 2026 |
| TRIUMPH-4 | Obesity + Knee Osteoarthritis | SUCCESS (28.7% Weight Loss) |
| TRIUMPH-8 | Obesity + Weight Maintenance | Estimated July 2027 |
Clinical Retatrutide Trial Eligibility Checklist: Can You Join?
If you want access to Retatrutide before 2027, your only legal option is to join an active clinical trial. As of January 2026, select specialized trials are still managing participants or recruiting for long-term outcomes.
Standard Inclusion Criteria:
- [ ] BMI Requirement: You must have a BMI of ≥30.0 kg/m², or ≥27.0 kg/m² if you have a weight-related condition like high blood pressure or sleep apnea.
- [ ] Age: Must be 18 years or older.
- [ ] Diet History: Proof of at least one unsuccessful dietary effort to lose weight.
- [ ] Medication Gap: You must not have used other weight loss medications (like Wegovy or Zepbound) within the last 90 days.
Standard Exclusion Criteria:
- [ ] Pancreatitis: Personal history of acute or chronic pancreatitis.
- [ ] Surgery: Prior bariatric surgery or planned surgery during the trial period.
- [ ] Specific Cancers: Personal or family history of medullary thyroid carcinoma (MTC).
FAQ: Your 2026 Retatrutide Clinical Trial Questions Answered
Is Retatrutide "legal" right now?
Will it be a pill or a shot?
How does it compare to Zepbound (Tirzepatide)?
Ready to Start Your Weigvht Loss Journey Today? While Retatrutide is still in trials, existing FDA-approved medications like Tirzepatide and the new Wegovy Pill are currently available.